scholarly journals Effect of dietary inclusion of black soldier fly larvae (Hermetia illucens) on broiler performance: A meta-analysis

2022 ◽  
Vol 335 ◽  
pp. 00013
Author(s):  
Sandi Nayohan ◽  
Irwan Susanto ◽  
Dessy Permata ◽  
Raiza Tri Pangesti ◽  
Mardiah Rahmadani ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Mixed Model ◽  
Meta Analysis ◽  
Average Daily Gain ◽  
Live Weight ◽  
Blood Metabolites ◽  
P Value ◽  
Black Soldier Fly ◽  
Hermetia Illucens ◽  
Broiler Performance

Black Soldier Fly (BSF, Hermetia illucens) is an insect species that potentially can be used as a protein source for broiler nutrition. This study aimed to evaluate different inclusion level of BSF on broiler performance and blood metabolites by integrating various data from related studies using meta-analysis. Total of 12 studies that comprised of 31 data points were integrated in the database. Parameters observed included Live Weight (LW), Average Daily Gain (ADG), Daily Feed Intake (DFI), Feed Conversion Ratio (FCR), blood metabolites, and carcass proportion. The database was statistically analyzed by using mixed model method. Different studies were considered as random effects, and the level of BSF was treated as fixed effects. The model statistics used were the p-values and the Akaike information criterion. The significance of an effect was stated when its p-value was < 0.05. The results revealed that BSF feeding had significant linearly reduction effect on LW, ADG, and FCR of broiler (P < 0.05) and significant linearly increase effect on DFI and carcass proportion. However, BSF did not significantly affect on blood metabolites of broilers. It can be concluded that BSF negatively affect the performance of broiler.

scholarly journals Incorporation of two levels of black soldier fly (Hermetia illucens L.) larvae fat or extruded linseed in diets of growing rabbits: effects on growth performance and diet digestibility

2018 ◽  
Vol 63 (No. 9) ◽  
pp. 356-362 ◽  
Author(s):  
Martins Cátia ◽  
Cullere Marco ◽  
Zotte Antonella Dalle ◽  
Cardoso Cristóvão ◽  
Alves Susana P ◽  
...  
Keyword(s):  
Growth Performance ◽  
Average Daily Gain ◽  
Live Weight ◽  
Ether Extract ◽  
Black Soldier Fly ◽  
Hermetia Illucens ◽  
Lipid Source ◽  
Gross Energy ◽  
Access To Water ◽  
Lipid Supplement

The use of black soldier fly (BSF) (Hermetia illucens L.) larvae fat as a lipid supplement in growing rabbit’s diet was evaluated at two levels of supplementation in comparison to two levels of extruded linseed. Forty-eight weaned rabbits aged 35 days were individually housed in digestibility cages and randomly allocated to one of the four diets: Linseed-Low (30 g/kg of fat from linseed), Linseed-High (60 g/kg of fat from linseed), BSF-Low (30 g/kg of BSF fat), BSF-High (60 g/kg of BSF fat). Animals had ad libitum access to water and feed during 5 weeks, and were slaughtered at 70 days of age. In the fourth week of the trial, faeces were collected to allow the evaluation of total tract apparent digestibility (TTAD) of the diets. Mortality, dry matter (DM) intake, average daily gain, slaughter live weight, and carcass, liver, perirenal fat, scapular fat, and digestive tract weights were not affected (P &gt; 0.05) either by fat source or fat level. The TTAD of DM, organic matter, ether extract, and gross energy were lower (P &lt; 0.05) in the diet containing BSF fat than in linseed diets, and the decrease observed ranged between 2.3 to 3.1 percent points. With increasing the fat inclusion level, ether extract TTAD increased (P &lt; 0.001) but the cellulose TTAD decreased (P &lt; 0.01). Overall, diets containing BSF fat resulted in a slightly lower TTAD than linseed diets, but this seemed not to have affected growth performance and carcass yield. In conclusion, BSF fat could be considered an alternative lipid source for growing rabbit diets highlighting similar productive results to linseed.

Meta-Analysis of Upper Probe Measurements in Normal Subjects and Patients with Laryngopharyngeal Reflux

2005 ◽  
Vol 114 (3) ◽  
pp. 177-182 ◽  
Author(s):  
Albert L. Merati ◽  
Seckin O. Ulualp ◽  
Hyun J. Lim ◽  
Robert J. Toohill
Keyword(s):  
Fixed Effects ◽  
Mixed Model ◽  
Laryngopharyngeal Reflux ◽  
Ph Monitoring ◽  
Meta Analysis ◽  
Normal Subjects ◽  
Acid Exposure ◽  
P Value ◽  
Fixed Effects Model ◽  
Significant Difference

We report a meta-analysis of a series of studies in which 24-hour ambulatory pH monitoring was performed in 1) normal subjects, 2) the normal control subjects in studies of laryngopharyngeal reflux (LPR), and 3) the patients with LPR in these controlled studies. The statistical analysis utilized the fixed-effects model by Mantel-Haenszel and the random-effects mixed model. There were 16 studies from the past 12 years that fulfilled the inclusion criteria. They involved 793 subjects (264 normal and 529 with LPR). The numbers of positive pharyngeal reflux events for normal subjects and for patients with LPR differed with a p value of <.0001. There was also a significant difference in the mean percentage of acid exposure times between normal subjects and patients with LPR (p = .003). We conclude that the upper probe gives accurate and consistent information in normal subjects and patients with LPR. The numbers of reflux events and acid exposure times are most important in distinguishing normal subjects from patients with LPR. The technology and methodology of probe testing is quite reliable and is consistent on a worldwide basis.

scholarly journals Performance, carcass traits, and relative organ weight of broiler supplemented by guanidinoacetic acid: A meta-analysis

2022 ◽  
Vol 951 (1) ◽  
pp. 012030
Author(s):  
Y Hardiyanto ◽  
A Jayanegara ◽  
R Mutia ◽  
S Nofyangtri
Keyword(s):  
Fixed Effects ◽  
Mixed Model ◽  
Meta Analysis ◽  
Average Daily Gain ◽  
Carcass Traits ◽  
Liver Weight ◽  
Feed Conversion ◽  
Guanidinoacetic Acid ◽  
Adenosyl Methionine ◽  
Daily Gain

Abstract Guanidinoacetic acid (GAA) is formed by the arginine and glycine that are catalysed by arginine:glycine amidinotransferase in the kidney. In the liver, GAA is methylated by s-adenosyl methionine and converted to creatine, then deposited into muscle as energy supply. This meta-analysis was done by integrating 20 articles from various journals. Supplementation doses ranged from 0 to 8000 ppm/kg feed. The mixed model methodology was employed with GAA level and broiler strain as fixed effects and studies as random effects. The results showed that increasing GAA level improved average daily gain day 0-21 and reduced feed conversion ratio day 0-35 (P<0.05). A higher GAA also accompanied by decreasing relative liver weight (P<0.05). GAA supplementation did not affect average daily feed intake and percentage of carcass traits (carcass, legs, breast, wings, drum, thigh) and other parameters such as abdominal fat, gizzard, heart, bursa, thymus and spleen (P>0.05). It was concluded that supplementation of GAA improved the performance of broilers.

scholarly journals Effect of zinc on the immune response and production performance of broilers: a meta-analysis

2020 ◽  
Vol 33 (3) ◽  
pp. 465-479 ◽  
Author(s):  
Cecep Hidayat ◽  
Anuraga Jayanegara ◽  
Elizabeth Wina
Keyword(s):  
Immune Response ◽  
Fixed Effects ◽  
Mixed Model ◽  
Positive Impact ◽  
Meta Analysis ◽  
Average Daily Gain ◽  
Production Performance ◽  
Organic Zinc ◽  
Zinc Concentrations ◽  
Inorganic And Organic

Objective: This study performed a meta-analysis of published trials to determine the effects of zinc on the immune response and production performance of broilers.Methods: A database was built from published literature regarding the addition of zinc forms or doses and their relation to the immune response and production performance of broilers. Different doses or forms of zinc were identified in the database. The recorded parameters were related to the immune response and production performance. The database contained a total of 323 data points from 41 studies that met the criteria. Then, the data were processed for a meta-analysis using a mixed model methodology. The doses or different forms of zinc were considered fixed effects, different studies were treated as random effects, and p-values were used as the model statistics.Results: An increase in zinc dose increased (p<0.05) pancreas metallothionein (MT) and zinc concentrations in the plasma, tibia and meat, all in quadratic patterns, but linearly decreased (p<0.05) the heterophil/lymphocyte (H/L) ratio. Regarding the different zinc forms, both inorganic and organic zinc increased (p<0.05) the zinc concentrations in the plasma and tibia, the calcium and phosphorus contents in the tibia, and the antioxidant activity of superoxide dismutase in meat as compared to control. An increase in zinc dose increased average daily gain (ADG) and decreased feed conversion ratio (FCR) following a quadratic pattern (p<0.05). Inorganic and organic zinc decreased (p<0.05) FCR and H/L ratio than that of control, but these two forms were similar for these parameters.Conclusion: Zinc addition has a positive impact on immunity and broiler production. Zinc can suppress stress and inhibit the occurrence of lipid peroxidation in broilers, and it can also improve ADG, FCR, and the quality of broiler carcasses.

scholarly journals PSX-7 Effect of varying levels of hempseed meal supplementation on animal performance, rumen fermentation, and blood metabolites of growing meat goats

2020 ◽  
Vol 98 (Supplement_4) ◽  
pp. 459-460
Author(s):  
Frank W Abrahamsen ◽  
Nar Gurung ◽  
Woubit Abdela ◽  
Gopal Reddy ◽  
Kim Mullenix
Keyword(s):  
Mixed Model ◽  
Average Daily Gain ◽  
Live Weight ◽  
Blood Chemistry ◽  
Optimal Level ◽  
Rumen Fermentation ◽  
Serum Glucose ◽  
Mixed Model Analysis ◽  
Meat Goats ◽  
Significant Difference

Abstract Hempseed meal (HSM) is a byproduct of hemp oil production and is high in crude protein, fiber, and fat, making it a potential feedstuff for ruminants. The objective of this study was to evaluate the effect of HSM supplementation on growth performance, rumen fermentation and blood chemistry profile of growing meat goats. Forty castrated, Boer cross goats were randomly assigned to one of the four treatments (n = 10): control, 10%, 20%, and 30% HSM supplementation. Data collected over a period of a 60-day feeding trial were analyzed utilizing the mixed model analysis function of SYSTAT, version 13. The result revealed total live weight gain decreased with the increasing levels of HSM supplementation 10.75, 9.53, 8.48, and 7.80 kg, for 0, 10, 20, and 30%, respectively. Average daily gain followed the same trend 0.179, 0.159, 0.141, and 0.13 kg, with a significant difference (P &lt; 0.05) observed between the control and 30 % supplementation. Conversely, feed to gain ratio increased with the increasing levels of supplementation 9.0, 10.2, 11.9, 12.2, likewise a significant difference was observed (P &lt; 0.05) between the control and 30% supplementation. Acetic, propionic, butyric, valeric, iso-valeric, and iso-butyric acid concentrations as well as the total VFA concentration decreased significantly (P &lt; 0.05) with the increasing level of supplementation. Acetic to propionic acid ratios increased with increasing level of supplementation 3.43, 4.36, 4.52, and 4.59, significant differences (P &lt; 0.05) were observed between control-20% and 30% HSM group. Serum glucose concentration decreased with an increasing rate of HSM supplementation while BUN concentration increased with no significant differences. These findings provide new insights into the feeding value of HSM for meat goats; however, further research needs to be conducted to determine the optimal level of supplementation.

PSXIV-4 Meta-analysis of the effects of monensin on growth and bloat of growing beef calves on pasture

2021 ◽  
Vol 99 (Supplement_3) ◽  
pp. 468-469
Author(s):  
Shane Gadberry ◽  
David Lalman ◽  
Frank White ◽  
Sara Linneen ◽  
Paul A Beck
Keyword(s):  
Meta Analysis ◽  
Average Daily Gain ◽  
Negative Control ◽  
Day Length ◽  
P Value ◽  
Sufficient Information ◽  
Ample Evidence ◽  
Dose Study ◽  
High Forage ◽  
Forage Diets

Abstract This meta-analysis investigated the impacts of monensin on performance of stocker cattle on high-forage diets. The stocker performance analysis resulted from 38 experiments with 73 mean comparisons; bloat analysis was conducted with 12 experiments with 23 mean comparisons. The metaphor package (version 2.4-0) for R (version 4.0.3; www.r-project.org) was used to determine the overall effect size of monensin compared to a negative control. Each study’s n, means, and SEM or P-value was used to calculate the mean difference and estimate of within study variance for responses of interest. Moderators of monensin response considered in the analysis were delivery method, dose, study duration, initial calf BW, diet ME and CP, and forage category. Initial BW and basal ADG averaged 236 ± 45.9 kg and 0.72 ± 0.28 kg/day, respectively. In the ADG analysis the only significant moderator of those considered was length of the study (P &lt; 0.01), as duration of the study increased the ADG response to monensin decreased by 0.0007 kg/day. For the average 112-day length of study, the average monensin response is estimated to be 0.0784 kg/day increase in average daily gain. Sufficient information was presented in only 18 citations representing 40 mean comparisons for determining the effect of monensin on BW at the end of the experiment, estimated by (P &lt; 0.01) monensin response (increased ending BW, kg) = 22.3 – 0.05 (initial calf BW, kg). Thus, for the average initial BW of 235 kg the average monensin response is estimated to be 10.6 kg increase in average ending BW. The incidence (-20%) and severity (-0.7 bloat scores) of bloat was found to be reduced in bloat prone pastures. There is ample evidence that monensin increases performance of growing calves on high forage diets along with reducing the incidence and severity of bloat.

Comparison of fixed effects and mixed model growth functions in modelling and predicting live weight in pigs

2015 ◽  
Vol 177 ◽  
pp. 8-14 ◽  
Author(s):  
J.M. Coyne ◽  
D.P. Berry ◽  
E.A. Mäntysaari ◽  
J. Juga ◽  
N. McHugh
Keyword(s):  
Fixed Effects ◽  
Mixed Model ◽  
Live Weight ◽  
Growth Functions

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5344-5344 ◽  
Author(s):  
Ajay K. Nooka ◽  
Jonathan L. Kaufman ◽  
Madhusmita Behera ◽  
Charise Gleason ◽  
Hannah Collins ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Research Funding ◽  
Mixed Model ◽  
Meta Analysis ◽  
Phase Iii ◽  
P Value ◽  
Serious Adverse Events ◽  
Early Relapse ◽  
The Impact ◽  
Relapsed Myeloma

Abstract Introduction: Controversy exists regarding the choice of triplet versus doublet salvage therapy among patients with multiple myeloma (MM) experiencing early relapse. Triplet therapies produce deeper responses (CR, ≥VGPR, ORR) and result in prolonged progression free survival (PFS) while doublet therapies demonstrate an improved toxicity profile. We performed a meta-analysis of the RCTs comparing triplet to doublet salvage regimens in early relapsed myeloma patients (1-3 prior lines of therapy). The objective is to test the hypothesis that triplet regimens are tolerable, improve CR, ≥VGPR, ORR rates and would translate to an improved PFS. Methods: We searched Pubmed, Cochrane databases and ASH, ASCO conference proceedings from 01/2000 through 07/2015 for publications and abstracts to identify the phase III RCTs comparing triplet vs. doublet salvage therapies among patients with relapsed myeloma. A meta-analysis of 4 RCTs (PANORAMA1, MMVAR/IFM 2005-04, ASPIRE, ELOQUENT2 consisting of 2475 patients) was performed using the fixed (Mantel-Haenszel) and random (DerSimonain and Laird) models to calculate the impact of triplets versus doublets (table 1) by evaluating the CR, ≥VGPR, ORR, PFS and toxicities. Mature OS data was not available for the RCTs, hence not included in meta-analysis. The consistency of results (effect sizes) among studies was investigated by means of 2 heterogeneity tests: the χ 2-based Cochran's Q test, and the I2 Statistic. We considered that heterogeneity was present when the P-value of the Cochran's Q test was <.1 and the I2 statistic was > 50%. Results: The pooled odds ratios of ORR, ≥VGPR and CR with triplets vs. doublets were 1.935 (P <0.000; 95% CI: 1.614-2.321); 2.185 (P <0.000; 95% CI: 1.832-2.606); 2.461 (P <0.000; 95% CI: 1.888-3.207) respectively, indicating that the odds of achieving higher quality responses are improved with triplet regimens compared to the use of a doublet regimens. The pooled hazard ratio (HR) for PFS was 0.661 (95% CI 0.596-0.734; P =0.000) in favor of triplet regimens (Figure 1). The Q-statistic for PFS (P =0.725; df =3; I2 = 0.00) suggests homogeneity across studies. Though the relative risk of selected ≥grade 3 serious adverse events (G3 SAE) was higher with triplet regimens (diarrhea, fatigue, thrombocytopenia 2.288 (95% CI 1.637-3.197; P =0.000), 1.654 (95% CI 1.263-2.166; P =0.000), 2.434 (95% CI 1.934-3.063; P =0.000), respectively), the overall G3 SAE were comparable with RR 1.498 (95% CI 1.176-1.908; P =0.001) favoring doublets. Conclusion: Our mixed model meta-analysis demonstrates that triplet regimens in early relapsed myeloma patients result in improved ORR, ≥VGPR, CR and PFS compared to doublets. G3 SAEs are higher with triplet regimens, however this appears to be influenced by the regimen-related toxicity from the PANORAMA1 trial. Appropriate dose modifications or use of selective HDAC inhibitors in future may mitigate the toxicities of the regimen. The pooled estimates ofresponse and survival strongly favor triplets in the early relapsed setting. Table 1. Triplet vs. doublet regimens in RCTs Trial Triplet regimen Doublet regimen PANORAMA1 Panobinostat, bortezomib, dexamethasone Placebo, bortezomib, dexamethasone MMVAR/IFM 2005-04 Bortezomib, thalidomide, Dexamethasone Thalidomide, Dexamethasone ASPIRE Carfilzomib, lenalidomide, Dexamethasone Lenalidomide, Dexamethasone ELOQUENT 2 Elotuzumab, lenalidomide, Dexamethasone Lenalidomide, Dexamethasone Figure 1. VGPR rates and PFS with triplet vs. doublet regimens Figure 1. VGPR rates and PFS with triplet vs. doublet regimens Disclosures Nooka: Spectrum Pharmaceuticals: Consultancy; Onyx Pharmaceuticals: Consultancy. Kaufman:Onyx: Consultancy; Celgene: Consultancy; Novartis: Research Funding; Onyx: Research Funding; Merck: Research Funding; Janssen: Consultancy; Spectrum: Consultancy; Novartis: Consultancy. Gleason:Onyx: Consultancy; Novartis: Consultancy; Celgene: Consultancy. Lonial:Janssen: Consultancy, Research Funding; Onyx: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Celgene: Consultancy, Research Funding.

Hand–foot skin reaction, an anticipated dermatologic toxicity to pazopanib, with an unexpected low incidence: A systematic review of literature and meta-analysis.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 365-365 ◽  
Author(s):  
Y. Balagula ◽  
S. Wu ◽  
X. Su ◽  
M. E. Lacouture
Keyword(s):  
Clinical Trials ◽  
Tyrosine Kinases ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Statistical Significance ◽  
P Value ◽  
High Grade ◽  
Multikinase Inhibitor ◽  
Systematic Analysis ◽  
Dermatologic Toxicity

365 Background: Pazopanib is a novel multikinase inhibitor that has been approved for the treatment of advanced renal cell carcinoma (RCC). It shares a similar spectrum of target receptors with sorafenib and sunitinib, including VEGFR, PDGFR, and c-kit tyrosine kinases. We have performed a systematic analysis to investigate the risk of HFSR to pazopanib. Exploring the differences in the incidence of HFSR between sorafenib, sunitinib, and pazopanib may offer additional insights into underlying mechanisms of this toxicity. Methods: Relevant studies were identified from PubMed (1998-2010) and abstracts presented at the American Society of Clinical Oncology Conferences between 2004 and 2010. Eligible studies were limited to prospective phase II-III clinical trials in which cancer patients were treated with pazopanib 800 mg orally once daily. Incidence, relative risk (RR), and 95% confidence intervals were calculated using random-effects or fixed-effects models based on the heterogeneity of included studies. Results: A total of 942 patients from 10 prospective clinical trials were included in the analysis. The overall incidence of all-grade and high-grade HFSR was 4.5% (95% CI: 2.5-7.9%) and 1.5% (95% CI: 0.7-3.1 %), respectively. The relative risks of all-grade and high-grade HFSR to pazopanib monotherapy in comparison with controls were increased, reaching statistical significance for all-grade (RR=6.05, 95% CI: 1.11-33.12, p=0.038), but not for high-grade (RR=2.51, 95% CI: 0.12-51.9, p=0.55). The incidence of all-grade HFSR was significantly higher in patients with RCC as compared to patients with non-RCC malignancies (7.8% vs. 2.4%, p value=0.015). Conclusions: Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis. [Table: see text]

Risk of fall and clinical fracture associated with androgen receptor inhibitors: A systematic review and meta-analysis.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 71-71
Author(s):  
Zin Myint ◽  
Harry D. Momo ◽  
Danielle E. Otto ◽  
Donglin Yan ◽  
Robert S. DiPaola ◽  
...  
Keyword(s):  
Systematic Review ◽  
Androgen Receptor ◽  
Phase Ii ◽  
Fixed Effects ◽  
Mixed Model ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Phase Iii ◽  
High Grade ◽  
Increased Risk

71 Background: Patients treated with androgen receptor inhibitors (ARIs) report a higher incidence of falls; although a potential mechanism of action is unknown. This systematic review evaluates the relative risk (RR) of fall and fracture in prostate cancer (PCa) patients that receive ARIs. Methods: We conducted a comprehensive literature search using Cochrane, Scopus and MedlinePlus databases from inception through August 2019, and evaluated all published prospective phase II, III and IV randomized controlled trials that treated PCa patients with ARIs. Reported fall and fractures as adverse events (AEs) were extracted for analysis. Retrospective, phase I, non-randomized phase II, and studies with control arms that used one of the ARIs were excluded. A mixed effects model was used to estimate effects of ARI on the RR, with the included studies treated as random effects and study arms treated as fixed effects in the pooled analysis. Sample size for each study was used to weight the mixed model. Results: Eleven studies met our inclusion criteria. The total population was 11,382; 6536 were in the ARI arm and 4846 in the control (CTL) arm. Study types were: 8 phase III; 2 phase II; 1 phase IV. Subjects in the ARI arm received enzalutamide, apalutamide or darolutamide in combination with androgen deprivation therapy or other enzalutamide combinations while in the CTL arm received placebo, bicalutamide or abiraterone. Treatment duration ranged from 5.4 to 20.5 mo for ARI vs. 5.4 to 18.3 mo for CTL. The reported incidence of fall was 481 (7.4%) in ARI and 201 (4.1%) for CTL. The incidence of fracture was 204 (3.1%) in ARI and 93 (1.9%) in control. The use of ARI was associated with an increased risk: all fall grades (RR 1.83; 95% CI 1.56-2.15; p <0.01); high grade fall (RR 1.69; 95% CI 1.09 – 2.62; p=0.019); all grade fracture (RR 1.56; 95% CI 1.23-1.97; p <0.01) and likely high grade fracture (RR 1.62; 95% CI 0.97 – 2.69; p=0.063). Conclusions: The use of ARI significantly increases falls and fractures in PCa patients as assessed by this meta-analysis study. Further studies would be warranted to identify and understand potential mechanisms and develop strategies to decrease falls and fractures associated with ARI use.

Sign in / Sign up

Export Citation Format

Share Document